The 2012 Immunogenicity for Biotherapeutics Agenda is Available for Download

We are pleased to announce that the brochure for IIR’s 13th-annual “Immunogenicity for Biotherapeutics” is now available for you to download! The most trusted event for Immunogenicity experts just got even better: guided by your feedback, we’ve changed the format and the flow, and added an all-new lineup of never-before-heard case studies and all-new summits. This year’s program offers something for everyone, from the most highly specialized immunochemists to scientists just starting their assay design and interpretation work. As the largest and longest-running conference devoted to designing safer molecules and reliable assays, no other event provides more cutting edge scientific insights.  Immunogenicity for Biotherapeutics will take place April 17-19, 2012, in Baltimore, Maryland.

Over 40 Immunogenicity experts address the four most important challenges facing pharmaceutical scientists today. Their case studies will help you:

• • Predict Immunogenicity through a Better Understanding of its Underlying Causes
• • Plan and Confirm Improvements in Clinical Assay Design
• • Prevent Immunogenicity through Advances in Protein Engineering and Tolerance Induction
• • Prepare for Breakthroughs in Immunogenicity Considerations for Biosimilars and Biobetters

Why is IIR’s Immunogenicity Event the Only Event You Need to Attend All Year?
It is the only event to provide:

• → Up-to-the-minute interactive briefings from FDA regulators, which will guide you to avoid mistakes and design consistently worthwhile assay and reporting methods.
• → A major emphasis on predicting and matching the immunogenic profiles of biosimilars and biobetters, which will help you – personally – lead your company to success and safety away from the “patent cliff.”
• → A detailed workshop on setting and understanding cutpoints and outliers to boost your skills and the efficiency and reliability of your results.
• → Multiple sessions and an in-depth workshop devoted to modifying biologics to minimize epitopes, which will prove essential to your de-risking approach.

To see the all new agenda, download the brochure here.

Share this article with your social network, just click below to share now!

Share |